



Six Presentations at the ADA Annual Meeting will Highlight Data on VIVUS' Qnexa

MOUNTAIN VIEW, Calif., June 22, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa(R), an investigational drug candidate, will be featured in a total of six presentations - including an oral presentation, three moderated poster presentations and two poster presentations - during the 70th Scientific Sessions of the American Diabetes Association (ADA), being held from June 25-29, 2010 in Orlando, Florida.

"VIVUS is pleased to have such a robust presence at this year's ADA annual meeting and to have leading experts in obesity, diabetes and cardiometabolic disease presenting data that we believe further highlight the potential impact Qnexa, if approved, may have on the life-threatening comorbidities associated with obesity," commented Leland Wilson, chief executive officer of VIVUS. "As the rates of obesity and their related illnesses continue to grow, we believe that Qnexa may provide patients and their physicians with a much-needed drug therapy in the treatment of this disease. We value this opportunity for engagement with the medical community to share the Qnexa diabetic and glycemc data with experts in this field."

Following are details about the presentations:

70th Scientific Sessions of the American Diabetes Association (ADA),
Orange Country Convention Center, Orlando, Fla.

Date and Time: Monday, June 28, 2010, 5:45-6:00 PM

Location: Room 314

Session: Oral Presentation Session

Abstract: 577ADA10D1

Poster: 382-P

Presentation Title: A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients With Type 2 Diabetes Mellitus (T2DM) or Prediabetes

Presenter: Kishore Gadde, M.D.

Date and Time: Sunday, June 27, 2010, 12:00-2:00 PM /Monday, June 28, 12:00-2:00 PM

Location: Hall C

Session: Poster Presentation Session /Moderated Poster Presentation Session

Abstract: 2465ADA10D1

Poster: 1847-P

Presentation Title: Magnitude of Weight Loss Experienced With a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate May Drive Degree of Cardiometabolic Benefit

Authors: Kishore M. Gadde, MD; Thomas Najarian, MD; Wesley W. Day, PhD

Date and Time: Sunday, June 27, 2010, 12:00-2:00 PM /Monday, June 28, 12:00-2:00 PM

Location: Hall C

Session: Poster Presentation Session /Moderated Poster Presentation Session

Abstract: 3251ADA10D

Poster: 1842-P

Presentation Title: Changes in Insulin Sensitivity, and Insulin Secretion in Overweight/Obese Patients Treated With Low-Dose,

Controlled-Release Phentermine/Topiramate

Authors: W. Timothy Garvey, MD; Kishore M. Gadde, MD; Peter Tam; Craig Peterson, MS

Date and Time: Sunday, June 27, 2010, 12:00-2:00 PM /Monday, June 28, 12:00-2:00 PM

Location: Hall C

Session: Poster Presentation Session /Moderated Poster Presentation Session

Abstract: 2491ADA10D1

Poster: 1846-P

Presentation Title: Low-Dose, Controlled-Release Phentermine/Topiramate and Markers of Type 2 Diabetes Mellitus

Authors: Donna H. Ryan, MD; Kishore M. Gadde, MD; Peter Tam; Barbara Troupin, MD

Date and Time: Sunday, June 27, 2010, 12:00-2:00 PM

Location: Hall C

Session: Poster Presentation Session

Abstract: 3266ADA10D1

Poster: 1083-P

Presentation Title: Improvements in Dyslipidemia and Other Cardiometabolic Disease Risk Factors With Low-Dose, Controlled-Release Phentermine/Topiramate

Authors: W. Timothy Garvey, MD; Kishore M. Gadde, MD; Leland Wilson; Craig Peterson, MS

Date and Time: Sunday, June 27, 2010, 12:00-2:00 PM

Location: Hall C

Session: Poster Presentation Session

Abstract: 2500ADA10D1

Poster: 1879-P

Presentation Title: Effects of Low-Dose, Controlled-Release Phentermine/Topiramate on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus

Authors: Donna H. Ryan, MD; Kishore M. Gadde, MD; Leland Wilson; Barbara Troupin, MD

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the

Securities and Exchange Commission.

CONTACT:

VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
650-934-5200

Investor Relations: The Trout Group
Brian Korb
646-378-2923

Media Relations: Pure Communications,
Inc.
Dan Budwick
973-271-6085

SOURCE VIVUS, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved